Aromatase Inhibitors and Newly Developed Nonalcoholic Fatty Liver Disease in Postmenopausal Patients with Early Breast Cancer: A Propensity Score‐Matched Cohort Study
Conclusion.Results of this study suggest that inhibition of estrogen synthesis in postmenopausal women undergoing treatment with aromatase inhibitors could increase the risk of NAFLD, which might have some influence on the prognosis of patients with breast cancer.Implications for Practice.Unlike tamoxifen, the role of aromatase inhibitor treatment use in postmenopausal patients with breast cancer in development of fatty liver is not well known. In this propensity‐matched cohort study, postmenopausal patients with breast cancer treated with aromatase inhibitors had increased risk of nonalcoholic fatty liver disease compared with healthy women after menopause, independent of obesity and diabetes mellitus. The results show possible adverse influence of the newly developed fatty liver on breast cancer disease‐free survival and suggest a necessity for further validation. Fatty liver may need to be considered as an adverse event for aromatase inhibitor treatment.
AbstractBackgroundUntil now, there is no clear conclusion on the relationship between the surgical margin status after radical prostatectomy (RP) and prostate cancer-specific mortality (PCSM). Therefore, we conducted this systematic review and meta-analysis based on all eligible case –control studies.MethodsA systematic and comprehensive literature search was performed based on PUBMED and EMBASE to identify all of the potentially relevant publications which were published before September 2019. Hazard ratio (HR) for PCSM was independently extracted by two reviewers from all eligible studies. Pooled HR estimates with ...
AbstractPurposeTo identify patients with metastatic urothelial cancer (mUC) unlikely to benefit from immune-checkpoint inhibitors (ICIs).Methods/PatientsWe explored the predictive and prognostic values of baseline neutrophil-to-lymphocyte ratio (NLR), with cut-offs ≥ 3 and ≥ 5, and of a urothelial immune prognostic index (UIPI, based on increased NLR and LDH), on 146 patients.ResultsNLR and UIPI significantly predicted progressive disease and progression-free survival with both cut-offs (p = 0.0069,p = 0.0034,p = 0.0160,p = 0.0063;p
ConclusionsIn conclusion, both the venous access catheter selection algorithm and the proposed recommendations aim to respond to the needs revealed in clinical practice and to become an integrable tool in electronic prescription systems to offer homogeneous criteria for action in cancer patients that require venous access, optimizing the use of available health resources with the highest safety and quality of life for the patient.
ConclusionmiR-1976 may serve as a promising non-invasive biomarker for the diagnosis of BC in the future.
AbstractIn this update of the consensus of the Spanish Society of Medical Oncology (Sociedad Espa ñola de Oncología Médica—SEOM) and the Spanish Society of Pathology (Sociedad Española de Anatomía Patológica—SEAP), advances in the analysis of biomarkers in advanced colorectal cancer (CRC) as well as susceptibility markers of hereditary CRC and molecular biomarkers of localized CRC are reviewed. Recently published information on the essential determination ofKRAS,NRAS andBRAF mutations and the convenience of determining the amplification of human epidermal growth factor ...
Expect another 30 to 40 years of increasing numbers of HPV-related oropharynx cancers, said an expert.Medscape Medical News
Publication date: Available online 20 September 2020Source: Materials Today: ProceedingsAuthor(s): Mohd Javeed Mehdi, N Srinivasrao, A Sireesha
Presentation of CF, airway clearance regimens, diabetes in CF, and other highlights from the cystic fibrosis episode of The Cribsiders podcast.Medscape Pediatrics
Conclusions: Bariatric surgery appears to be capable of partially reversing the obesity-related epigenome. The identification of potential epigenetic biomarkers predictive for the success of bariatric surgery may open new doors to personalized therapy for severe obesity. Introduction Obesity is currently a huge healthcare problem, worldwide, and is a risk factor for several diseases such as type 2 diabetes (T2D), cardiovascular disease and cancer (1). As the prevalence of obesity reaches pandemic proportions, this metabolic disease is estimated to become the biggest cause of mortality in the near future (2). In fact,...
More News: Breast Cancer | Cancer | Cancer & Oncology | Diabetes | Diabetes Mellitus | Eating Disorders & Weight Management | Endocrinology | Fatty Liver Disease (FLD) | Liver | Liver Disease | Men | Menopause | Non-alcoholic Fatty Liver Diseases (NAFLD) | Obesity | Statistics | Study | Tamoxifen | Urology & Nephrology | Women